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The dysregulation of immune checkpoints by tumors is an
important mechanism of immune resistance, as adminis-
tration of checkpoint inhibitors has resulted in impressive
clinical responses in patients with late stage cancers. How-
ever, a subset of patients exhibits insufficient or no clinical
response presumably due to the absence of tumor-specific
cytotoxic T lymphocytes (CTLs). This supports the ratio-
nale to combine checkpoint inhibitors with therapeutic
platforms that generate effector T cells.
We have previously shown that the lentiviral vector
platform, ZVexTM, generates high levels of tumor anti-
gen-specific CTLs that are critical in mediating protec-
tion against tumor challenge in mice. Protection was
enhanced by subsequent intramuscular injections of
recombinant tumor antigen protein with GLA-SE (for-
mulated glucopyranosyl lipid A, a synthetic TLR4 agonist
that is the central component of the GLAASTM platform)
or intratumoral injections of G100 (GLA-SE without pro-
tein antigen). ZVex and GLAAS are thus complementary
platforms capable of generating tumor-specific immunity
through the in vivo induction of antigen-specific T cells.
Here, we evaluated whether checkpoint blockade could
further enhance anti-tumor immunity induced by ZVex
and/or GLAAS in mouse tumor models.
In C57BL/6 mice, anti-PD-1 or anti-PD-L1 – but not
anti-CTLA4 – enhanced a ZVex/mTRP1-induced CD8
T cell response. To determine whether checkpoint inhi-
bition impacted therapeutic efficacy, B16F10 tumor-
bearing mice were immunized with ZVex/mTRP1
followed by weekly administrations of anti-PD-1, anti-
PD-L1, or anti-CTLA4. Mirroring the immunogenicity
results, ZVex/mTRP1-induced anti-tumor protection
was enhanced by the addition of anti-PD-1 or anti-PD-
L1, but not anti-CTLA4. This is consistent with
previous studies in which we demonstrated that the
magnitude of antigen-specific CTL response correlated
with the degree of anti-tumor protection. Additionally,
compared to either anti-PD-1 or anti-PD-L1 alone, the
combined administration of both checkpoint inhibitors
best improved anti-tumor efficacy induced by ZVex/
mTRP1, or G100, or the combination of ZVex/mTRP1
and GLA-SE/TRP1 protein. As PD-L1 is not the only
ligand for PD-1 and PD-1 is not the only receptor for
PD-L1, these findings suggest that inhibition of signaling
through either PD-1 or PD-L1 alone may not be suffi-
cient to completely block the PD-1/PD-L1 checkpoint.
Taken together, combining checkpoint inhibitors with
ZVex and GLAAS capitalizes on the strength of each ther-
apeutic platform. ZVex and GLAAS efficiently generate
the effector T cells needed for an effective anti-tumor
response. By blocking active immune checkpoints, check-
point inhibitors further enhance ZVex- and/or GLAAS-
induced anti-tumor immunity. Our findings support the
combination of checkpoint inhibitors with ZVex and/or
GLAAS in clinical trials.
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